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background
 
The use of involved-field radiotherapy after chemotherapy for advanced Hodgkin’s
lymphoma is controversial.
 
methods
 
We randomly assigned patients with previously untreated stage III or IV Hodgkin’s
lymphoma who were in complete remission after hybrid chemotherapy with mechlor-
ethamine, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, and vin-
blastine (MOPP-ABV) to receive either no further treatment or involved-field radiother-
apy. Radiotherapy consisted of 24 Gy to all initially involved nodal areas and 16 to 24 Gy
to all initially involved extranodal sites. Patients in partial remission were treated with
30 Gy to nodal areas and 18 to 24 Gy to extranodal sites.
 
results
 
Of 739 patients, 421 had a complete remission; 161 of these patients were assigned to
no further treatment, and 172 to involved-field radiotherapy. The median follow-up was
79 months. The five-year event-free survival rate was 84 percent in the group that did not
receive radiotherapy and 79 percent in the group that received involved-field radiother-
apy (P=0.35). The five-year overall survival rates were 91 and 85 percent, respectively
(P=0.07). Among the 250 patients in partial remission after chemotherapy, the five-year
event-free and overall survival rates were 79 and 87 percent, respectively.
 
conclusions
 
Involved-field radiotherapy did not improve the outcome in patients with advanced-
stage Hodgkin’s lymphoma who had a complete remission after MOPP-ABV chemo-
therapy. Radiotherapy may benefit patients with a partial response after chemotherapy.
abstract
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he outcome of treatment for ad
 
-
vanced Hodgkin’s lymphoma has improved
dramatically over the past two decades.
Cure rates of more than 70 percent are now possi-
ble
 
1-10
 
 with a hybrid regimen of mechlorethamine,
vincristine, procarbazine, prednisone, doxorubicin,
bleomycin, and vinblastine (MOPP-ABV); a regimen
of doxorubicin, bleomycin, vinblastine, and dacar-
bazine (ABVD); or a regimen of bleomycin, etopo-
side, doxorubicin, cyclophosphamide, vincristine,
procarbazine, and prednisone (BEACOPP).
The potential role of radiotherapy after the com-
pletion of chemotherapy in patients with advanced
Hodgkin’s lymphoma stems from the observations
that relapses usually occur at initially involved sites
and that radiotherapy lowers the rates of recur-
rence.
 
11
 
 The results of several randomized studies
have, however, raised questions about the benefit
of adjuvant radiotherapy.
 
9,11-16
 
 Moreover, a combi-
nation of chemotherapy and radiotherapy may in-
crease the risks of late complications, especially sec-
ond cancers and cardiovascular disease.
 
17-21
 
 These
risks must be balanced against the risk of treatment
failure, since patients who have no response to ini-
tial therapy or who have an early relapse are not like-
ly to be cured by salvage treatment.
 
22-24
 
A previous European Organization for Research
and Treatment of Cancer Lymphoma Group trial in
patients with advanced Hodgkin’s lymphoma used
a response-adapted strategy consisting of six cycles
of chemotherapy instead of eight in patients who
had a complete remission after four cycles.
 
3
 
 The
assumption was that two additional cycles of che-
motherapy would consolidate an early complete re-
mission, provided that a total of six cycles were giv-
en.
 
25
 
 These considerations led to the present trial
to determine whether radiotherapy reduces the re-
lapse rate among patients with stage III or IV Hodg-
kin’s lymphoma who have a complete remission
after six to eight cycles of MOPP-ABV hybrid chemo-
therapy (considered the standard chemotherapy at
the time the trial was designed).
 
patients
 
Patients with previously untreated stage III or IV
Hodgkin’s lymphoma who were 15 to 70 years of
age were eligible for the study. Ineligibility criteria
were pathological stage IIIA
 
S
 
 with splenic involve-
ment as the only site of infradiaphragmatic disease;
severe cardiac, pulmonary, or metabolic disease; and
a previous diagnosis of cancer (except for nonmela-
noma skin tumors and cervical carcinoma in situ).
All pathological specimens were to be reviewed, but
this was not a criterion for eligibility. The protocol
was submitted to and approved by the ethics com-
mittee of each participating center, and oral in-
formed consent was required before enrollment.
 
pretreatment workup
 
The following studies were required on enrollment:
physical examination, complete blood count, meas-
urement of the erythrocyte sedimentation rate, se-
rum biochemical tests, a chest film, computed to-
mography (CT) of the chest, ultrasonography of the
liver and spleen, bipedal lymphangiography (or ab-
dominal CT where available), and unilateral bone
marrow biopsy. Liver biopsy, bone scanning, and
gallium scintigraphy were performed if indicated
but were not required. After four cycles of chemo-
therapy, all examinations that had initially abnormal
results (including bone marrow biopsy) were re-
peated.
Bulky disease was defined as a mass of at least
10 cm (largest diameter) or a bulky mediastinum
(a ratio of the mediastinum to the thorax of at
least 0.35 at the level of T5 through T6 while the
patient was standing).
 
26
 
 Complete remission was
defined as the disappearance of all disease-relat-
ed symptoms and measurable lesions, including
normalization of blood values and findings on ra-
diologic examination and bone marrow–biopsy
specimens.
 
27
 
chemotherapy
 
MOPP-ABV hybrid chemotherapy was administered
to all patients in the following doses: mechloretha-
mine, 6 mg per square meter of body-surface area
given intravenously on day 1; vincristine, 1.4 mg per
square meter (maximal dose, 2 mg) given intrave-
nously on day 1; procarbazine, 100 mg per square
meter given orally on days 1 through 7; predni-
sone, 40 mg per square meter given orally on days 1
through 14; doxorubicin, 35 mg per square meter
given intravenously on day 8; bleomycin, 10 mg per
square meter given intramuscularly or intravenous-
ly on day 8; and vinblastine, 6 mg per square meter
given intravenously on day 8. Chemotherapy was
given every 28 days for a total of six to eight cycles.
Patients were evaluated after four cycles of che-
motherapy (Fig. 1). Those with progressive disease
or no change in their condition were excluded from
the study. All other patients received two additional
t
methods
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Figure 1. Study Protocol and Numbers of Patients with a Complete Response, a Partial Response, or No Response.
 
MOPP-ABV denotes mechlorethamine, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, and vinblastine 
hybrid.
739 Patients received
4 cycles of MOPP-ABV
718 Could be 
evaluated
447 Had a partial
response
247 Had a complete
response
6 Had treatment
failure
2 Cycles of 
MOPP-ABV
17 Had treatment
failure
68 Excluded
from study
2 Cycles of 
MOPP-ABV
421 Had a complete
response
88 Did not undergo 
randomization
(24 received involved-
field radiotherapy)
333 Underwent
randomization
161 Had no further
treatment
172 Received involved-
field radiotherapy
24 Had treatment
failure
21 Could not be
evaluated
250 Had a partial
response
227 Received involved-
field radiotherapy
191 Had a complete
response
2 Cycles of
MOPP-ABV
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cycles of MOPP-ABV chemotherapy. Patients who
were in complete remission after four cycles and
who remained in complete remission after six cycles
(early complete remission) were randomly assigned
to receive no further treatment or involved-field ra-
diotherapy. Patients who were in partial remission
after four cycles and who were in complete remis-
sion after six cycles (late complete remission) were
given two additional cycles of chemotherapy before
undergoing randomization. Patients who remained
in partial remission after six cycles stopped receiving
chemotherapy and were treated with involved-field
radiotherapy.
 
involved-field radiotherapy
 
Patients in complete remission received 24 Gy of
radiation to nodal regions; those in partial remis-
sion received 30 Gy (with a boost of 4 to 10 Gy if
needed) in fractions of 1.5 to 2.0 Gy. The spleen
was included in the radiation field when the para-
aortic nodes were involved. If the spleen was in-
volved in the absence of known paraaortic node
disease, the radiation fields encompassed both the
spleen and the paraaortic nodes. If there was lung
involvement initially, a dose of 16 Gy was pre-
scribed after a complete remission, and a dose of
18 Gy was prescribed after a partial remission with
a localized boost of 4 to 10 Gy when necessary. If
the liver was involved, 20 Gy of radiation was giv-
en, and if bone was involved, a dose of 24 Gy was
given to affected areas (with a boost of 10 Gy when
necessary).
The dose was defined according to the guidelines
of report 29 of the International Commission on Ra-
diation Units and Measurements.
 
28
 
 Involved-field
radiotherapy started within six to eight weeks after
the first day of the last cycle of chemotherapy and
was administered in one to three courses, depend-
ing on the extent of the original involvement.
 
statistical analysis
 
The primary objective of the study was to determine
whether adjuvant radiotherapy improved three-year
relapse-free survival in patients who had a complete
remission after six to eight cycles of MOPP-ABV.
Secondary end points were event-free survival and
overall survival.
Relapse-free survival was calculated from the
date of assessment of complete remission (after four
or six cycles of chemotherapy) to the date of the first
relapse, the date of the last examination, the date of
death, or June 1, 2002, whichever came first. Event-
free survival was calculated for all patients from the
first day of chemotherapy to the date of the first
event (treatment failure, relapse, or death from any
cause), the date of the last examination, or June 1,
2002, whichever came first. Overall survival was cal-
culated from the first day of chemotherapy to the
date of death, the date of the last examination, or
June 1, 2002, whichever came first. The time to the
development of a second cancer was calculated
from the first day of chemotherapy to the date on
which the second cancer was diagnosed, the date
of death, the date of the last examination, or June 1,
2002, whichever came first. The cumulative proba-
bility of a second cancer was calculated as 1 minus
the probability of survival without the development
of a second cancer.
Relapse-free survival, event-free survival, overall
survival, and the cumulative probability of a second
cancer were estimated according to the Kaplan–
Meier method, and the rates in each group were
compared with use of the log-rank test. Ninety-five
percent confidence intervals for the rates were esti-
mated with use of the method of Rothman and
Boice.
 
29
 
 All analyses were performed according
to the intention-to-treat principle. Two-sided tests
were used in reporting the results. Stata statistical
software was used to analyze data.
 
30
 
Assuming a rate of complete remission of 70
percent and a three-year relapse-free survival rate
of 80 percent after chemotherapy with MOPP-ABV,
we needed to enroll 321 patients who were in com-
plete remission and who had data that could be eval-
uated, in order for the study to have the power to
demonstrate a 10 percent increase in survival (i.e.,
90 percent vs. 80 percent) after adjuvant involved-
field radiotherapy (
 
a
 
=0.05 and 
 
b
 
=0.20 by the log-
rank test and a one-sided test).
Forty-two cooperating centers in Belgium,
France, Italy, the Netherlands, Poland, Portugal, and
Slovenia participated. Registration, randomization,
and data collection were performed at the Depart-
ment of Biostatistics and Epidemiology, Institut
Gustave Roussy, Villejuif, France. Randomization
was stratified according to the center, and treatment
assignments were provided by telephone or fax ma-
chine. Data were stored with use of a specific data-
management program (PIGAS) developed at the
Institut Gustave Roussy.
 
31
 
 Data were updated on
June 1, 2002. The median follow-up period was 79
months.
The New England Journal of Medicine 
Downloaded from nejm.org at RADBOUD UNIVERSITEIT NIJMEGEN on March 6, 2017. For personal use only. No other uses without permission. 
 Copyright © 2003 Massachusetts Medical Society. All rights reserved. 
 n engl j med 
 
348;24
 
www.nejm.org june 
 
12
 
, 
 
2003
 
The
 
 new england journal 
 
of
 
 medicine
 
2400
 
* Because of rounding, percentages may not total 100.
† Bulky mediastinum was defined, in patients with mediastinal involvement, as a ratio of mediastinum to thorax of at least 0.35 at the level of 
T5 through T6 while the patient was standing.
 
26
 
‡ Bulky disease was defined as a mass of at least 10 cm (largest diameter) or a bulky mediastinum.
§ The overall duration of treatment was defined as the time from the start of chemotherapy to the start of the last chemotherapy cycle plus one 
 
month or to the end of the radiotherapy course among patients who received involved-field radiotherapy.
 
Table 1. Characteristics of the Patients.*
Characteristic
Total
(N=739) Complete Remission
Partial
Remission
(N=250)
No Change,
Progression, Death,
or Could Not Be
Evaluated
(N=68)
 
No
Radiotherapy
(N=161)
Radiotherapy
(N=172)
Not
Randomized
(N=88)
Age — yr
Median
Range
33
14–71
32
15–70
36
14–70
34
16–70
30
15–70
44
15–71
Male:female ratio 1.79:1 1.73:1 1.77:1 1.67:1 1.66:1 3.00:1
Site of disease — no. (%)
Supradiaphragmatic
Infradiaphragmatic
Both
106 (14)
18 (2)
615 (83)
19 (12)
2 (1)
140 (87)
23 (13)
5 (3)
144 (84)
14 (16)
5 (6)
69 (78)
44 (18)
3 (1)
203 (81)
6 (9)
3 (4)
59 (87)
Stage — no. (%)
IIIA
IIIB
IVA
IVB
191 (26)
238 (32)
96 (13)
214 (29)
46 (29)
50 (31)
20 (12)
45 (28)
46 (27)
61 (35)
19 (11)
46 (27)
14 (16)
26 (30)
16 (18)
32 (36)
77 (31)
74 (30)
32 (13)
67 (27)
8 (12)
27 (40)
9 (13)
24 (35)
Mediastinal involvement — no. (%)
Bulky mediastinum†
598 (81)
208 (35)
132 (82)
29 (22)
139 (81)
42 (30)
65 (74)
22 (34)
217 (87)
96 (44)
45 (66)
19 (42)
Bulky disease — no. (%)‡ 311 (42) 55 (34) 63 (37) 33 (38) 127 (51) 33 (49)
No. of extranodal sites of disease in pa-
tients with stage IV — no. (%)
1
2
≥3
310
203 (65)
75 (24)
32 (10)
65
43 (66)
17 (26)
5 (8)
65
40 (62)
19 (29)
6 (9)
48
32 (67)
12 (25)
4 (8)
99
67 (68)
21 (21)
11 (11)
33
21 (64)
6 (18)
6 (18)
Extranodal locations
Lungs
Liver
Bone
Bone marrow
132 (43)
77 (25)
57 (18)
83 (27)
24 (37)
13 (20)
13 (20)
23 (35)
24 (37)
18 (28)
13 (20)
22 (34)
19 (40)
13 (27)
6 (12)
18 (38)
54 (55)
18 (18)
19 (19)
14 (14)
11 (33)
15 (45)
6 (18)
6 (18)
Albumin <40 g/liter — no./total no. (%) 297/596 (50) 65/130 (50) 67/136 (49) 41/72 (57) 88/203 (43) 36/55 (65)
Histologic review — no. (%)
Lymphocyte predominant
Nodular sclerosis
Mixed cellularity
Hodgkin’s lymphoma of unspecified 
subtype
Non-Hodgkin’s lymphoma
Diagnosis of Hodgkin’s lymphoma 
uncertain
660
12 (2)
516 (78)
98 (15)
1 (<1)
20 (3)
13 (2)
144
2 (1)
112 (78)
26 (18)
0
1 (1)
3 (2)
157
3 (2)
117 (75)
28 (18)
0
6 (4)
3 (2)
74
1 (1)
54 (73)
14 (19)
0
4 (5)
1 (1)
228
2 (1)
196 (86)
21 (9)
1 (1)
5 (2)
3 (1)
57
4 (7)
37 (65)
9 (16)
0
4 (7)
3 (5)
Overall duration of treatment — mo§
Median
Range
8.0
1–19
6.0
3–11
9.0
5–19
7.5
5–14
9.0
5–16
4.0
1–10
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clinical characteristics and response 
to chemotherapy
 
From September 1989 to April 2000, a total of 739
patients were enrolled (Fig. 1). Table 1 shows the
characteristics of the patients. The diagnosis of
Hodgkin’s lymphoma was confirmed in 627 of the
660 reviewed cases. Of the 33 patients with uncon-
firmed cases, the diagnosis of Hodgkin’s lympho-
ma was uncertain in 13 and excluded in 20 (includ-
ing 14 patients with non-Hodgkin’s lymphoma).
These 20 patients were equally distributed among
the five subgroups of patients.
Of the 739 patients who received chemotherapy,
421 (57 percent) had a complete remission, 250 (34
percent) had a partial remission, 7 had no change,
26 had progressive disease, 14 died during therapy,
and 21 could not be evaluated (Fig. 1 and Table 1).
Of the 208 patients with bulky mediastinal disease,
93 (45 percent) had a complete remission and 96
(46 percent) had a partial remission. Among pa-
tients without bulky mediastinal disease, these pro-
portions were 62 percent and 30 percent, respec-
tively (P<0.001). Sixty-seven percent of the patients
received six cycles of chemotherapy, and 26 percent
received eight cycles; 7 percent stopped receiving
chemotherapy because of progressive disease or
poor tolerance.
Among the 421 patients in complete remission,
161 were randomly assigned to receive no radiother-
apy and 172 to receive involved-field radiotherapy.
The two groups had similar clinical characteristics
(Table 1). Eighty-eight patients in complete remis-
sion did not undergo randomization because of the
patient’s refusal in 38 cases, the physician’s refusal
in 32 cases, a protocol violation in 16 cases, and un-
specified reasons in 2 cases. Twenty-four of these
88 patients received radiotherapy, and 64 had no
further treatment.
 
acute toxicity
 
During or after chemotherapy, grade 3 (moderate)
or grade 4 (severe) hematologic toxicity developed
in 48 to 60 percent of patients, depending on the
number of cycles of chemotherapy given; eight pa-
tients died of sepsis. Grade 3 or 4 radiation-related
hematologic toxicity occurred in 16 percent of pa-
tients and was significantly more likely to occur in
patients with previous severe toxicity due to che-
motherapy than in those without such a history
(P=0.01). Grade 3 or 4 radiation-related pulmo-
nary toxicity occurred in three patients. No deaths
were related to acute toxicity of radiotherapy.
 
outcome among patients 
in complete remission
 
After a median follow-up of 79 months, the relapse-
free survival rates and event-free survival rates (Fig.
2) were similar among patients in complete remis-
sion who did not receive radiotherapy and patients
in complete remission who received involved-field
radiotherapy. There was no significant difference
between the two groups in overall survival (hazard
ratio, 0.57; 95 percent confidence interval, 0.31 to
1.06; P=0.07): 10 percent of the patients who did
not receive radiotherapy died, as compared with 16
percent of those who received involved-field radio-
therapy. Overall, 14 percent of patients had relapses.
The relapses were confined to originally involved
sites in 11 of 24 patients who did not receive radio-
therapy and in 6 of 22 patients who received in-
volved-field radiotherapy.
 
outcome among patients who did not 
undergo randomization
 
The event-free and overall survival rates among pa-
tients who were not randomly assigned to a treat-
ment but who had a complete or partial remission
after chemotherapy were similar to those among pa-
tients who underwent randomization (Fig. 3 and
results
 
Figure 2. Kaplan–Meier Estimates of Event-free Survival among Patients 
in Complete Remission after Chemotherapy Who Were Randomly Assigned 
to Receive Either No Radiotherapy or Involved-Field Radiotherapy.
 
There was no significant difference between groups (P=0.35 by the log-rank test).
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Table 2). Among such patients, the main causes of
death were progressive disease and second cancers.
Patients in whom MOPP-ABV treatment failure oc-
curred or who could not be evaluated had a very poor
outcome (Fig. 3 and Table 2).
 
effect of pathological review
 
Among the 577 patients with a confirmed diagnosis
of Hodgkin’s lymphoma and a complete or partial
response to chemotherapy, the five-year event-free
and overall survival rates were 80 percent and 88
percent, respectively, as compared with 59 percent
(P=0.02) and 65 percent (P=0.008), respectively,
among the 16 patients with a complete or partial re-
sponse who were found not to have Hodgkin’s lym-
phoma after a pathological review.
 
second cancers
 
A second cancer developed 9 to 112 months after
the initiation of treatment in 6 patients in the group
that did not receive radiotherapy and in 15 patients
in the group that received involved-field radiother-
apy; the five-year cumulative rates of second can-
cers were 4.0 percent and 7.8 percent, respectively
(P=0.05) (Table 2). In the other groups, the five-year
cumulative rates of second cancers approached that
among patients with a complete remission who
were assigned to receive no radiotherapy. Of the 15
cases of acute leukemia or myelodysplasia, which
occurred 10 to 99 months after the initiation of
treatment, 13 developed in patients who were irradi-
ated (including one patient who received radiation
for a relapse).
The objective of this trial was to determine whether
radiotherapy to all initially involved areas reduces
the relapse rate among patients with stage III or IV
Hodgkin’s lymphoma who have a complete remis-
sion after MOPP-ABV chemotherapy. Our random-
ized trial involving 333 patients in complete re-
mission failed to show that radiotherapy increases
event-free or overall survival. These results under-
line the effectiveness of modern chemotherapy.
Whereas a meta-analysis
 
6
 
 suggested that chemo-
therapy alone is sufficient treatment provided that
eight cycles are administered, our findings indicate
that six to eight cycles of MOPP-ABV produce very
good results.
In the Southwest Oncology Group’s randomized
trial of involved-field radiotherapy, the 49 percent
of patients who had a complete response after six
cycles of nitrogen mustard, vincristine, prednisone,
bleomycin, doxorubicin, and procarbazine (MOP-
BAP) were randomly assigned to receive involved-
field radiotherapy or no further treatment.
 
14
 
 No
overall benefit from radiotherapy was observed; in
patients with bulky, nodular sclerosing Hodgkin’s
lymphoma, however, the relapse-free survival rate
was significantly higher after involved-field radio-
therapy. A possible explanation for the difference
discussion
 
Figure 3. Kaplan–Meier Estimates of Overall Survival According to the Patients’ Response to Initial Chemotherapy 
and to Whether They Underwent Randomization.
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* MOPP-ABV denotes mechlorethamine, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, and vinblastine; NA not applicable; 
and CI confidence interval.
† The analysis was restricted to patients who received radiotherapy.
 
‡ The analysis of relapse-free survival was confined to the 421 patients who had a complete remission.
 
Table 2. Clinical Outcome.*
Outcome
Total
(N=739) Complete Remission
Partial
Remission
(N=250)
No Change,
Progression, Death,
or Could Not
Be Evaluated
(N=68)
 
No
Radiotherapy
(N=161)
Radiotherapy
(N=172)
Not
Randomized
(N=88)
Complete remission — no. (%)
After 4 cycles of MOPP-ABV
After 6 cycles of MOPP-ABV
237 (33)
421 (57)
101 (63)
161 (100)
105 (61)
172 (100)
31 (35)
88 (100)
NA
NA
NA
NA
Progression or relapse — no. (%) 130 24 22 17 45 22
Site of progression or relapse
Nodal only
Extranodal only
Nodal and extranodal
Unspecified
71 (55)
5 (4)
44 (34)
10 (7)
18 (75)
1 (4)
5 (21)
0
14 (64)
2 (9)
6 (27)
0
10 (59)
0
7 (41)
0
22 (49)
2 (4)
21 (47)
0
7 (32)
0
5 (23)
10 (45)
Relation to original site
Confined to original site
New site
Both
Unspecified
49 (38)
25 (19)
46 (35)
10 (8)
11 (46)
2 (8)
11 (46)
0
6 (27)
9 (41)
7 (32)
0
7 (41)
5 (29)
5 (29)
0
19 (42)
8 (18)
18 (40)
0
6 (27)
1 (5)
5 (23)
10 (45)
Relation to irradiation field†
Within field
Outside field
Both
Unspecified or not applicable
74
15 (20)
33 (45)
25 (34)
1 (1)
NA
NA
NA
NA
NA
22
5 (23)
12 (54)
5 (23)
0
5
2 (40)
2 (40)
1 (20)
0
45
8 (18)
19 (42)
18 (40)
0
2
0
0
1 (50)
1 (50)
5-Yr relapse-free survival — % (95% CI)‡ 83 (79–87) 84 (77–89) 85 (79–90) 77 (66–85) NA NA
5-Yr event-free survival — % (95% CI) 75 (72–78) 84 (77–89) 79 (72–85) 73 (61–81) 79 (73–84) 24 (13–36)
Death — no. (%)
Progressive disease
Treatment-related
Initial treatment
Salvage treatment
Second cancer
Intercurrent disease
Unspecified cause
131
63 (48)
16 (12)
6 (5)
28 (21)
16 (12)
2 (2)
16
9 (56)
0
2 (12)
4 (25)
1 (6)
0
28
7 (25)
2 (7)
2 (7)
11 (39)
5 (18)
1 (4)
18
7 (39)
1 (6)
1 (6)
6 (33)
3 (17)
0
31
21 (68)
2 (6)
0
5 (16)
2 (6)
1 (4)
38
19 (50)
12 (32)
0
2 (5)
5 (13)
0
5-Yr overall survival — % (95% CI) 83 (80–86) 91 (84–94) 85 (78–90) 87 (77–93) 87 (82–91) 31 (19–44)
All second cancers — no. (%)
Type of second cancer — no. (%)
Acute leukemia or myelodysplasia
Non-Hodgkin’s lymphoma
Solid tumor outside radiation field
Solid tumor within radiation field
Myeloma
40
15 (37)
3 (8)
15 (38)
6 (15)
1 (2)
6
1 (17)
1 (17)
4 (67)
0
0
15
8 (53)
2 (13)
2 (13)
3 (20)
0
7
4 (57)
0
3 (43)
0
0
10
2 (20)
0
4 (40)
3 (30)
1 (10)
2
0
0
2 (100)
0
0
5-Yr cumulative rate — % (95% CI) 4.7 (3.2–6.9) 4.0 (1.6–9.3) 7.8 (4.4–13.7) 3.1 (0.8–11.8) 3.2 (1.4–7.0) 10.4 (2.6–37)
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between these results and ours is that in the South-
west Oncology Group study the number of cycles
of chemotherapy was not changed if there was a
response. Alternatively, MOPP-ABV chemotherapy
may be a more effective regimen than the MOP-BAP
regimen, reducing the potential advantage of radio-
therapy.
In the German Hodgkin’s Study Group trial, pa-
tients with intermediate stages of Hodgkin’s lym-
phoma who were in complete remission after che-
motherapy were assigned to receive one additional
cycle of chemotherapy (49 patients) or 20 Gy of in-
volved-field radiotherapy (51 patients).
 
13
 
 There was
no significant difference in outcome between the
two groups. The Groupe d’Études des Lymphomes
de l’Adulte has recently reported the results of a ran-
domized trial comparing two additional cycles of
doxorubicin-containing chemotherapy with total or
subtotal nodal irradiation in patients with a com-
plete or good partial remission of stage IIIB or IV
Hodgkin’s lymphoma. Although the radiotherapy
was more extensive and the dose (30 Gy) was higher
than the one we used, the outcome was similar in
the two groups.
 
9
 
These randomized trials highlight the impor-
tance of a chemotherapy-induced complete remis-
sion. The determination of complete remission is
cumbersome, however, because it is difficult to dis-
criminate between active disease and residual fibro-
sis. In our study, the outcome among patients with
a partial response who received involved-field radio-
therapy was similar to that among patients who
were considered to be in complete remission after
chemotherapy. However, a substantial proportion of
our patients identified as having a partial response
may actually have been in complete remission and
may not have needed radiotherapy. In some studies,
a partial remission after adequate first-line chemo-
therapy is considered an adverse prognostic factor,
and immediate second-line chemotherapy, includ-
ing high-dose regimens, is advised.
 
9
 
 Our results
suggest that such intensification of treatment is
unnecessary.
After a median follow-up of more than six years,
patients who received radiotherapy after a complete
remission had a higher rate of death from causes
other than Hodgkin’s lymphoma than did patients
who did not receive radiotherapy. The five-year cu-
mulative probability of a second cancer for patients
who received radiotherapy was nearly twice that for
patients who did not receive radiotherapy. Acute
leukemia or myelodysplasia accounted for the ma-
jority of second cancers in the radiotherapy group.
The risk of secondary acute leukemia is associated
with the use of alkylating chemotherapy
 
32,33
 
 and
especially with the dose of mechlorethamine.
 
34
 
 The
risk of leukemia is not increased after radiotherapy
alone,
 
35,36
 
 but radiotherapy may increase the risk of
leukemia if it is given after chemotherapy.
 
37,38
 
 This
issue remains controversial.
 
33-39
 
 To date, 12 of our
patients have had a solid tumor within the radiation
field. Since the risk of solid tumors is expected to
increase after radiotherapy, however, radiotherapy
should be avoided whenever possible. Combination
therapy with doxorubicin, bleomycin, vinblastine,
and dacarbazine (ABVD), by contrast, is associated
with a low rate of second cancers.
 
40
 
In conclusion, we found that there is no need
for involved-field radiotherapy to maintain remis-
sion in patients with stage III or IV Hodgkin’s lym-
phoma who are in complete remission after six to
eight cycles of MOPP-ABV hybrid chemotherapy.
The only patients who benefit from radiotherapy
are those in partial remission after chemotherapy.
 
Support for data evaluation was provided by the Ank van Vlissin-
gen Foundation, the Netherlands.
This article is dedicated to J. Marion V. Burgers, radiation oncolo-
gist at the Netherlands Cancer Institute, Amsterdam, who was in-
volved in the initiation of the trial and who died in 1997.
We are indebted to Peter Mauch, M.D., Ph.D., Harvard Medical
School, for his suggestions and careful review and editing of the text.
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